Rankings
▼
Calendar
URGN
UroGen Pharma Ltd.
$927M
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
+26.7% YoY
Gross Profit
$15M
86.8% margin
Operating Income
-$22M
-128.2% margin
Net Income
-$30M
-175.7% margin
EPS (Diluted)
$-1.30
QoQ Revenue Growth
-5.0%
Cash Flow
Operating Cash Flow
-$26M
Free Cash Flow
-$26M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$113M
Total Liabilities
$230M
Stockholders' Equity
-$117M
Cash & Equivalents
$37M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$17M
$14M
+26.7%
Gross Profit
$15M
$12M
+24.0%
Operating Income
-$22M
-$22M
-0.4%
Net Income
-$30M
-$28M
-6.4%
Revenue Segments
Jelmyto
$17M
100%
← FY 2023
All Quarters
Q2 2023 →
URGN Q1 2023 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena